Form 4: MAIA Biotechnology Director Acquires Stock Options

Director Jean-Manasse Theagene acquired 5,728 stock options in MAIA Biotechnology, Inc. on June 30, 2024.

Summary

• Jean-Manasse Theagene, a director of MAIA Biotechnology, Inc., filed a Form 4 on July 2, 2024, reporting a transaction.
• On June 30, 2024, Theagene acquired 5,728 stock options at a price of $3.42.
• These options, granted under the company's 2021 Equity Incentive Plan, vest immediately and are exercisable from the grant date.
• The options represent the right to buy 5,728 shares of common stock.
• Following the transaction, Theagene directly owns 5,728 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The grant of options could be seen as mildly positive, but it's a standard practice.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company director.

Key Dates